Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Kasper, Bernd ^a   Dimitrakopoulou Strauss, Antonia ^b   Pilz, Lothar R ^c   Strauss, Ludwig G ^b   Sachpekidis, Christos ^b   Hohenberger, Peter ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DESMOID TUMOR; DRUG DOSE ESCALATION; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOLOGICAL PARAMETERS; REVIEW; STANDARDIZED UPTAKE VALUE; TREATMENT RESPONSE; TUMOR BIOPSY; ARTICLE; CLINICAL TRIAL; FIBROMATOSIS; MIDDLE AGED; SCINTISCANNING; TREATMENT OUTCOME; YOUNG ADULT; DIAGNOSTIC USE; FIBROMATOSIS, AGGRESSIVE;

ADULT; AGED; BENZAMIDES; BIOLOGICAL MARKERS; FEMALE; FIBROMATOSIS, AGGRESSIVE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878702469     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/389672     Document Type: Review

References (30)

1. Biermann J. S., Desmoid tumors. Current Treatment Options in Oncology 2000 1 3 262 266 2-s2.0-0034256548
2. Micke O., Seegenschmiedt M. H., Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study. International Journal of Radiation Oncology Biology Physics 2005 61 3 882 891 2-s2.0-13844280893 10.1016/j.ijrobp.2004.07.705 (Pubitemid 40247987)
3. Bertario L., Russo A., Sala P., Varesco L., Giarola M., Mondini P., Pierotti M., Spinelli P., Radice P., Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. Journal of Clinical Oncology 2003 21 9 1698 1707 2-s2.0-0037797281 10.1200/JCO.2003.09.118 (Pubitemid 46638580)
4. Clark S. K., Phillips R. K. S., Desmoids in familial adenomatous polyposis. The British Journal of Surgery 1996 83 11 1494 1504 2-s2.0-0029950499 10.1002/bjs.1800831105 (Pubitemid 26365061)
5. Janinis J., Patriki M., Vini L., Aravantinos G., Whelan J. S., The pharmacological treatment of aggressive fibromatosis: a systematic review. Annals of Oncology 2003 14 2 181 190 2-s2.0-0037293572 10.1093/annonc/mdg064 (Pubitemid 36305427)
6. Pignatti G., Barbanti-Bròdano G., Ferrari D., Gherlinzoni F., Bertoni F., Bacchini P., Barbieri E., Giunti A., Campanacci M., Extraabdominal desmoid tumor: a study of 83 cases. Clinical Orthopaedics and Related Research 2000 375 207 213 2-s2.0-0342369605 (Pubitemid 30366592)
7. Druker B. J., Tamura S., Buchdunger E., Ohno S., Segal G. M., Fanning S., Zimmermann J., Lydon N. B., Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nature Medicine 1996 2 5 561 566 2-s2.0-0029947186
8. Demetri G. D., von Mehren M., Blanke C. D., Van den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D., Joensuu H., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine 2002 347 7 472 480 10.1056/NEJMoa020461 (Pubitemid 34879334)
9. Mace J., Biermann J. S., Sondak V., McGinn C., Hayes C., Thomas D., Baker L., Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002 95 11 2373 2379 2-s2.0-0036890418 10.1002/cncr.11029 (Pubitemid 35351145)
10. Leithner A., Gapp M., Radl R., Pascher A., Krippl P., Leithner K., Windhager R., Beham A., Immunohistochemical analysis of desmoid tumours. Journal of Clinical Pathology 2005 58 11 1152 1156 2-s2.0-27644540127 10.1136/jcp.2005.026278 (Pubitemid 41566458)
11. Heinrich M. C., McArthur G. A., Demetri G. D., Joensuu H., Bono P., Herrmann R., Hirte H., Cresta S., Koslin D. B., Corless C. L., Dirnhofer S., Van Oosterom A. T., Nikolova Z., Dimitrijevic S., Fletcher J. A., Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). Journal of Clinical Oncology 2006 24 7 1195 1203 2-s2.0-33644977853 10.1200/JCO.2005.04.0717 (Pubitemid 46638818)
12. Chugh R., Maki R. G., Thomas D. G., Reinke D., Wathen J. K., Patel S., Priebat D. A., Meyers P. A., Benjamin R. S., Baker L. H., A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Journal of Clinical Oncology 2006 24 18, abstract 9515
13. Schulte M., Brecht-Krauss D., Heymer B., Guhlmann A., Hartwig E., Sarkar M. R., Diederichs C. G., Schultheiß M., Kotzerke J., Reske S. N., Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? European Journal of Nuclear Medicine 1999 26 6 599 605 2-s2.0-0033056888 10.1007/s002590050427 (Pubitemid 29263630)
14. Eary J. F., Mankoff D. A., Tumor metabolic rates in sarcoma using FDG PET. Journal of Nuclear Medicine 1998 39 2 250 254 2-s2.0-0031916118 (Pubitemid 28114512)
15. Schuetze S. M., Rubin B. P., Vernon C., Hawkins D. S., Bruckner J. D., Conrad E. U., Eary J. F., Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005 103 2 339 348 2-s2.0-12344324487 10.1002/cncr.20769 (Pubitemid 40129294)
16. Schuetze S. M., Utility of positron emission tomography in sarcomas. Current Opinion in Oncology 2006 18 4 369 373 2-s2.0-33748067732 10.1097/01.cco.0000228744.49294.12 (Pubitemid 44297249)
17. Kasper B., Dimitrakopoulou-Strauss A., Strauss L. G., Hohenberger P., Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 10 1876 1882 2-s2.0-79952114035
18. Trojani M., Contesso G., Coindre J. M., Rouesse J., Bui N. B., de Mascarel A., Goussot J. F., David M., Bonichon F., Lagarde C., Soft-tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathological grading system. International Journal of Cancer 1984 33 1 37 42 2-s2.0-0021366779 (Pubitemid 14223231)
19. Schwarzbach M. H. M., Hinz U., Dimitrakopoulou-Strauss A., Willeke F., Cardona S., Mechtersheimer G., Lehnert T., Strauss L. G., Herfarth C., Büchler M. W., Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Annals of Surgery 2005 241 2 286 294 2-s2.0-19944432837 10.1097/01.sla.0000152663.61348.6f
20. Boellaard R., Krak N. C., Hoekstra O. S., Lammertsma A. A., Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. Journal of Nuclear Medicine 2004 45 9 1519 1527 2-s2.0-6944235697 (Pubitemid 47618506)
21. Cheng E. Y., Froelich J. W., Manivel J. C., Weigel J., Skubitz K. M., Correlation of FDG-PET with histologic response after neoadjuvant chemotherapy for soft tissue sarcomas. Proceedings of the American Society of Clinical Oncology 2009 25 18, abstract 10583
22. Kasper B., Dietrich S., Dimitrakopoulou-Strauss A., Strauss L. G., Haberkorn U., Ho A. D., Egerer G., Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography. Onkologie 2008 31 3 107 112 2-s2.0-40449083240 10.1159/000113795 (Pubitemid 351348089)
23. Jager P. L., Gietema J. A., van der Graaf W. T. A., Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nuclear Medicine Communications 2004 25 5 433 438 2-s2.0-2342453817 10.1097/00006231-200405000-00002 (Pubitemid 38591102)
24. Wahl R. L., Jacene H., Kasamon Y., Lodge M. A., From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. Journal of Nuclear Medicine 2009 50 supplement 1 122S 150S 2-s2.0-66149139452 10.2967/jnumed.108.057307
25. Penel N., Le Cesne A., Bui B. N., Perol D., Brain E. G., Ray-Coquard I., Guillemet C., Chevreau C., Cupissol D., Chabaud S., Jimenez M., Duffaud F., Piperno-Neumann S., Mignot L., Blay J. Y., Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Annals of Oncology 2011 22 2 452 457 2-s2.0-79251560032 10.1093/annonc/mdq341
26. Ramos-Font C., Chinchilla A. S., Aguirre A. C. R., Fernández A. R., Benítez A. M., Elvira J. M. L., Desmoid tumor of the chest wall characterized with 18F-fluorodeoxyglucose PET/CT scan. Correlation with magnetic resonancy and bone scintigraphy. Review of the literature. Revista Espanola de Medicina Nuclear 2009 28 2 70 73 2-s2.0-65449130774 10.1016/S0212-6982(09)70700- 1
27. Dimitrakopoulou-Strauss A., Strauss L. G., Egerer G., Vasamiliette J., Schmitt T., Haberkorn U., Kasper B., Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 8 1481 1489 2-s2.0-77956184902 10.1007/s00259-010- 1435-z
28. Dimitrakopoulou-Strauss A., Strauss L. G., Egerer G., Vasamiliette J., Mechtersheimer G., Schmitt T., Lehner B., Haberkorn U., Stroebel P., Kasper B., Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. Journal of Nuclear Medicine 2010 51 4 551 558 2-s2.0-77950925568 10.2967/jnumed.109.070862
29. Dimitrakopoulou-Strauss A., Hohenberger P., Pan L., Kasper B., Roumia S., Strauss L. G., Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a two-tissue compartment model. Clinical Nuclear Medicine 2012 37 10 943 948 10.1097/RLU.0b013e31825b1da4
30. Gounder M. M., Lefkowitz R. A., Keohan M. L., D'Adamo D. R., Hameed M., Antonescu C. R., Singer S., Stout K., Ahn L., Maki R. G., Activity of sorafenib against desmoid tumor/deep fibromatosis. Clinical Cancer Research 2011 17 12 4082 4090 2-s2.0-79959219259 10.1158/1078-0432.CCR-10-3322